|
Patient characteristics
|
Number
|
T790M (%)
|
P (Univariate)
|
P (Multivariate)
|
|---|
|
Age
| | |
0.9292
| |
|
≥75
|
12
|
4 (33%)
| | |
|
<74
|
49
|
17 (35%)
| | |
|
Sex
| | |
0.4904
| |
|
Female
|
44
|
14 (32%)
| | |
|
Male
|
17
|
7 (41%)
| | |
|
Smoking history
| | |
0.4904
| |
|
Never
|
44
|
14 (32%)
| | |
|
Former/current
|
17
|
7 (41%)
| | |
|
EGFR mutation status
| | |
0.1038
| |
|
Exon19 deletion
|
37
|
9 (24%)
| | |
|
Exon21 L858R
|
19
|
9 (47%)
| | |
|
Other
|
5
|
3 (60%)
| | |
|
Rebiopsy site
| | |
0.5813
|
0.9133
|
|
Central nervous system
|
11
|
3 (27%)
| | |
|
Other
|
50
|
18 (36%)
| | |
|
Rebiopsy sample
| | |
0.2017
|
0.5016
|
|
Tissue
|
28
|
12 (43%)
| | |
|
Fluid
|
33
|
9 (27%)
| | |
|
EGFR TKI
| | |
0.1208
| |
|
Gefitinib
|
49
|
17 (35%)
| | |
|
Erlotinib
|
7
|
4 (57%)
| | |
|
2nd generation
|
5
|
0 (0%)
| | |
|
Line of EGFR-TKI
| | |
0.4235
| |
|
1st
|
39
|
12 (31%)
| | |
|
2nd or later
|
22
|
9 (41%)
| | |
|
History of platinum doublet until rebiopsy
|
0.7021
| |
|
Yes
|
34
|
11 (32%)
| | |
|
No
|
27
|
10 (37%)
| | |
|
PFS with EGFR-TKI
| | |
0.4823
| |
|
≥10 months
|
34
|
13 (38%)
| | |
|
<10 months
|
27
|
8 (30%)
| | |
|
Interval between RECIST PD and rebiopsy
|
0.2766
| |
|
≥4 months
|
29
|
12 (41%)
| | |
|
<4 months
|
32
|
9 (28%)
| | |
|
Period of continuation of TKI beyond PD
|
0.0182
|
0.0417
|
|
≥30 days
|
20
|
11 (55%)
| | |
|
<30 days
|
41
|
10 (24%)
| | |
- Abbreviations: EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PFS progression free survival, PD progressive disease
